The broad goal of the proposed research is to investigate how lysine acetylation modifications of mitochondrial proteins regulate drug-induced liver injury (DILI). Acetyl modification of mitochondrial proteins is beginning to be recognized as a widespread post-translational modification, found on a diverse range of mitochondrial metabolic pathway proteins. SIRT3 is the-major mitchondiral deacetylace, and to date its deacetylation function has been shown to play a role in multiple biological insults including redox, genotoxic arid nutrient stressors. We recently found that SIRT3-/-mice are resistant to acetaminophen-induced liver injury. We hypothesize that increased acetylation of mitochondrial proteins might play an important role in DILI. We have identified several novel SIRT3 deacetylation targets, including mitochondrial aldehyde dehydrogenase 2 (ALDH2), apoptosis-inducing factor (AlF), ATP synthetase a-subunit (ATPa) and heat shock protein 10 (HSP10), which are indirectly implicated as targets in the development of DILI. Our preliminary data additionally shows a greater retention pf ALDH2 activity, and a reduction in toxic aldehyde levels, in S1RT3-/- mice. Furthermore, we show that in SIRT3-/- mice deacetylation ofALDH2 diminished the capacity of toxic acetaminophen metabolites to bind to ALDH2, and also have identified lysine residue functioning to this binding modulation. To further test our hypothesis, we will employ ALDH2 and AIF as the index proteins to explore and delineate the role that modulation of mitochondrial protein acetylation plays in DILI. In the proposed study, we will and investigate the role of lysine acetylation status in acetaminophen (APAP) metabolite binding, and its effect on ALDH2 function; susceptibility to acetaminophen hepatoxicity; and the potential therapeutic application of the ALD2 activator (Alda-1) in APAP hepatotoxicity. We will also investigate the acetylation status of AIF, ATPa, and HSP10 in regulating acetaminophen hepatotoxicity. We believe that this study will unmask novel functions of protein acetylation in modulating susceptibility to xenobiotic-induced liver injury. Increased understanding of this biology will have broad implications, aiding the development of strategies/therapies to alleviate the consequences of drug-induced liver injury.

Public Health Relevance

Drug-induced liver injury (DILI) is a serious health problem with high mortality and resource cost, and is the most common cause of acute liver failure in the USA. This research program will investigate how modification of proteins in cells regulates susceptibility to drug-induce liver injury. This will provide novel insights into the mechanism of DILI, and potentially aid in the development of new strategies for prophylaxis against and therapy for DILI.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Career Transition Award (K22)
Project #
5K22HL109236-04
Application #
8891476
Study Section
Special Emphasis Panel (NSS)
Program Officer
Carlson, Drew E
Project Start
2013-09-12
Project End
2016-07-31
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
4
Fiscal Year
2015
Total Cost
$249,000
Indirect Cost
$18,444
Name
George Washington University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
043990498
City
Washington
State
DC
Country
United States
Zip Code
20052
Lu, Zhongping; Chen, Yong; Aponte, Angel M et al. (2015) Prolonged fasting identifies heat shock protein 10 as a Sirtuin 3 substrate: elucidating a new mechanism linking mitochondrial protein acetylation to fatty acid oxidation enzyme folding and function. J Biol Chem 290:2466-76
Webster, Bradley R; Scott, Iain; Han, Kim et al. (2013) Restricted mitochondrial protein acetylation initiates mitochondrial autophagy. J Cell Sci 126:4843-9
Webster, Bradley R; Lu, Zhongping; Sack, Michael N et al. (2012) The role of sirtuins in modulating redox stressors. Free Radic Biol Med 52:281-90
Lu, Zhongping; Bourdi, Mohammed; Li, Jian H et al. (2011) SIRT3-dependent deacetylation exacerbates acetaminophen hepatotoxicity. EMBO Rep 12:840-6